Compugen Ltd - CGEN Net earnings per share for the last four quarters

Official company branding of Compugen Limited (CGEN)

Compugen Ltd. (CGEN) maintains a steady stream of funding through molecule licensing, powered by its proprietary oncology target discovery system. The company's price chart reflects EPS TTM dynamics, which currently stand at 230.20. The financial model relies on strategic alliances with pharma behemoths rather than mergers. High potential for AI-driven breakthroughs in cancer therapy attracts leading biologists and immunologists to the team.

Compugen (CGEN) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/12/2026

CGEN (Compugen Limited): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart Compugen Ltd.|CGEN - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Compugen Ltd|CGEN - Total Company Value
- book value of equity indicators:
Accounting Value per Share Compugen|CGEN - Company Book Value|Market Cap to Net Assets Ratio cgen.com|CGEN - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Compugen Ltd.|CGEN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Compugen Ltd.|CGEN - Company Debts|Debts to Book Value Compugen Ltd|CGEN - Company Long-Term Liabilities|Short-Term Indebtedness Compugen|Intermediate Liquidity Ratio cgen.com
- earnings and market multiples details:
CGEN - Net Profit|Expected Net Income Compugen Ltd.|CGEN - P/E Multiple|Projected Price to Earnings Ratio Compugen Ltd.|CGEN - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Compugen Ltd|CGEN - Operating profit EBITDA|Net earnings per share (EPS TTM) Compugen|CGEN - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months cgen.com|CGEN - Net earnings per share growth this year|Expected net earnings per share growth next year Compugen Ltd.
Initial company analysis:CGEN, Compugen
Mass-produced product of Compugen

The speculative potential of Compugen Ltd. (CGEN) is supported by its AI platform and payments from pharma behemoths, which minimize R&D risks. Analyzing the annual EPS TTM chart, an investor assesses the rate of change in net income per share over the last twelve months. This metric reveals the balance between cost inflation and real growth in business profitability. A stable trend confirms capital resilience and the effectiveness of the current intellectual property monetization strategy.

Direct competitors

Earnings per share for the trailing year IBRX (immunitybio.com)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Arcus Bio|Net earnings per share for the last 12 months Zymeworks Biopharmaceuticals (ZYME)|Earnings per share for the last twelve months Tango Therapeutics (TNGX)|Net earnings per share for the last 12 months iovance.com IOVA|Immatics - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc XNCR|CMPX - Earnings per share for the last twelve months|REPL (Replimune Inc.) - Earnings per share for the last 12 months|Lyell Immunopharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months innate-pharma.com (IPHA)|Net earnings per share for the last 12 months PYXS|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Therapeutics Inc (INTS) - Net earnings per one share for the last twelve months|Sensei Bio - Net earnings per share (EPS TTM)|therivabio.com (TOVX) - Net earnings per share for the last 12 months|gritstonebio.com (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta Inc (KA)|Earnings per share for the last twelve months NexImmune Corp|Net earnings per share for the last 12 months Turnstone Biologics Corporation (TSBX)|Earnings per share for the last twelve months Vaccinex, Inc. (VCNX)|HARP: Earnings per one share for the last 12 months